Tarsus Pharmaceuticals to Share Financial Highlights Soon

Author: Caleb Price Updated: 02-20-2025 05:33 PM

Upcoming Financial Results Announcement

Tarsus Pharmaceuticals, Inc. is gearing up to report its financial results for the fourth quarter and the full year 2024. The announcement is scheduled for a live webcast on a Tuesday morning at 5:00 a.m. PT, where company executives will share the latest numbers and details.

Webcast Access Details

Participants interested in the financial updates can easily join the webcast. The event promises to be informative, offering attendees comprehensive insights into Tarsus' financial performance and future strategies. Following the live session, a recorded version of the call will be made available shortly on the company's website, ensuring that stakeholders can access the information at their convenience.

About Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc. stands at the forefront of innovative treatments, focusing on transforming healthcare, particularly in the realm of eye care. By integrating proven scientific principles with groundbreaking technology, Tarsus is dedicated to addressing significant unmet medical needs.

Current Product and Pipeline Highlights

One of Tarsus’s key products, XDEMVY (lotilaner ophthalmic solution, 0.25%), has received FDA approval in the United States, representing a significant milestone in the treatment of Demodex blepharitis. This advancement showcases the company's commitment to improving the quality of life for patients suffering from this condition.

Moreover, Tarsus Pharmaceuticals is fervently working on other critical developments within its pipeline. The potential introduction of TP-04 for the treatment of Ocular Rosacea and TP-05, an oral tablet aiming to prevent Lyme disease, highlights the company's innovative spirit and dedication to addressing serious health challenges.

Media and Investor Relations

For those seeking further details or specific media inquiries, Tarsus has appointed Adrienne Kemp as the Senior Director of Corporate Communications. She is reachable at (949) 922-0801 for any media-related questions. Investors can connect with David Nakasone, the Head of Investor Relations, at (949) 620-3223 for insights into the company’s financial outlook and strategy discussions.

Company Contact Information

Tarsus Pharmaceuticals encourages interested parties to reach out through their contact points for further inquiries, signaling their commitment to transparency and open communication with stakeholders. Interested individuals can email media inquiries to AKemp@tarsusrx.com and investor-related questions to DNakasone@tarsusrx.com.

Frequently Asked Questions

What is the date and time of the financial results webcast?

The webcast is scheduled for a Tuesday at 5:00 a.m. PT.

How can I access the recorded version of the webcast?

The recorded version will be available on Tarsus Pharmaceuticals' website shortly after the live event.

What is XDEMVY, and what condition does it treat?

XDEMVY is a solution approved by the FDA for treating Demodex blepharitis, a common eyelid condition.

Who can I contact for media inquiries at Tarsus Pharmaceuticals?

Media inquiries can be directed to Adrienne Kemp, Senior Director of Corporate Communications.

What are the future developments being pursued by Tarsus?

Tarsus is developing TP-04 for Ocular Rosacea treatment and TP-05 as a potential prevention for Lyme disease.

About The Author

Hey there I'm Caleb Price, a writer and financial specialist who loves to assist others in understanding the financial world. Having years of practical experience and a solid background in finance, my area of expertise is converting difficult financial ideas into useful, doable insights for my blog and publications. My goal with my writing is to give readers the information and assurance they need to successfully negotiate their financial journeys.

My ability to interact with a wide range of people—from novices starting their investing journey to seasoned investors looking for new approaches—has come from contributing to several financial blogs. Making money approachable and understandable is my goal; this will enable you to make wise choices and realize your financial objectives. We appreciate you coming along on this path to success and financial empowerment on Investors Hangout.

Contact Caleb Price privately here. Or send an email with ATTN: Caleb Price as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.